Canada markets closed

Telesis Bio, Inc. (TBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4400+0.0099 (+2.30%)
At close: 04:00PM EDT
0.4250 -0.01 (-3.41%)
After hours: 07:05PM EDT

Telesis Bio, Inc.

10431 Wateridge Circle
Suite 150
San Diego, CA 92121-2993
United States
858 228 4115
https://telesisbio.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees223

Key Executives

NameTitlePayExercisedYear Born
Dr. Todd R. Nelson MBA, Ph.D.Founder, CEO & Director924.38kN/A1967
Mr. Daniel G. Gibson Ph.D.Chief Technology Officer590.37kN/A1977
Mr. Robert H. CutlerChief Legal Officer568.58kN/A1968
Mr. Eric EsserPresident & COON/AN/A1968
Mr. William J. KullbackChief Financial OfficerN/AN/A1960
Ms. Jen CarrollVice President of Investor RelationsN/AN/AN/A
Mr. Decky Goodrich M.B.A.Senior Vice President of Corporate DevelopmentN/AN/AN/A
Ms. Laura B. Puga M.B.A.Vice President of People & CultureN/AN/A1980
Mr. Laurence WardenSenior Vice President of Engineering & InstrumentationN/AN/AN/A
Richard LepkeDirector of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits, such as BioXp De Novo kits, BioXp select kits, BioXp next generation sequencing kits, and BioXp DBC kits, which contains building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and short oligo ligation assembly enzymatic DNA synthesis designs to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins compared to traditional chemical synthesis, paving the way for more efficient and effective development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Corporate Governance

Telesis Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.